Traders should monitor for upcoming full data readouts and potential partnerships or trial expansions; the current market cap of $59M may not reflect the potential value of these results if confirmed in larger trials.
Price Chart
Executive Summary
PDS Biotechnology announced preliminary data from a trial using its PDS01ADC technology, showing a 78% objective response rate and over 80% two-year survival rate, compared to 35% and ~35% respectively in a parallel trial without PDS01ADC. These results suggest a potentially significant clinical improvement for the company's cancer therapy platform.
Key Facts
- PDS01ADC trial showed 78% objective response rate vs 35% in control arm
- Two-year survival rate exceeded 80% with PDS01ADC vs ~35% without
- Data appears to demonstrate strong efficacy signal for PDSB's ADC platform
Financial Impact
Potential revaluation of PDSB's platform given strong survival and response rates in early data
Risk Factors
- Data is preliminary and from a non-randomized parallel trial, raising potential selection bias
- Small sample sizes could skew response and survival rates
- Lack of regulatory approval path details or timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274455 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | 8-K | $0.3000 $0.5853 | ▼ −95.10% | ▼ −96.22% | $0.7485 (−149.50%) |
Aug 19, 2026 6w ago | 8-K | $0.2089 $0.2179 | ▲ +4.31% | ▲ +3.19% | $0.7485 (+258.31%) |
Aug 13, 2026 7w ago | 8-K | $0.2332 $0.2089 | ▲ +10.42% | ▲ +8.46% | $0.7485 (−220.97%) |
Aug 11, 2026 7w ago | 8-K | $0.2570 $0.2080 | ▲ +19.07% | ▲ +18.66% | $0.7485 (−191.25%) |
Jul 22, 2026 10w ago | EFFECT | $0.7155 $0.6696 | ▲ +6.42% | ▲ +4.01% | $0.7485 (−4.61%) |
Jun 26, 2026 13w ago | DEFA14A | $0.8991 $0.8461 | ▼ −5.89% | ▼ −7.28% | $0.7485 (−16.75%) |
Jun 15, 2026 15w ago | 8-K | $0.9600 $0.9120 | ▲ +5.00% | ▲ +2.77% | $0.7485 (+22.03%) |
Jun 15, 2026 15w ago | 8-K | $1.02 $0.9412 | ▼ −7.73% | ▼ −6.34% | $0.7485 (−26.62%) |
Jun 2, 2026 17w ago | 8-K | $1.16 $1.03 | ▼ −11.21% | ▼ −8.24% | $0.7485 (−35.47%) |
May 13, 2026 20w ago | Press Release | $1.33 $1.00 | ▼ −24.81% | ▼ −23.65% | $0.7485 (−43.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access